2 recruiting, 2 withdrawn, 1 no longer available, 1 suspended. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Suspended 1, Withdrawn 1 |
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
Follow Leland Metheny: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT Cellular therapy product - Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia | Phase 1 | Withdrawn | Leland Metheny | 2024-12-01 | 2024-12-05 | |
| hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) P140K-MGMT, O6-benzylguanine, Photon Based Radiotherapy - Glioblastoma Multiforme, Glioblastoma Multiforme, Adult | Phase 2 | Recruiting | Leland Metheny | 16 | 2023-01-20 | 2026-09-10 |
| Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD Fecal Microbiota Transplantation (FMT) - Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD) | Phase 2 | Withdrawn | Leland Metheny | 2022-05-01 | 2022-07-07 | |
| Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia Inotuzumab Ozogamicin - Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Leland Metheny | 44 | 2017-07-31 | 2026-09-10 |
| Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts. Allogenic T cell-depleted hematopoietic stem cell transplantation - Hematopoietic/Lymphoid Cancer | No longer available | Leland Metheny | 2025-03-12 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Myelodysplastic Syndromes (2) · Glioblastoma (1) · Graft vs Host Disease (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma (1) · Lymphoproliferative Disorders (1) · Myeloproliferative Disorders (1)
Abatacept (1) · Carmustine (1) · Cyclophosphamide (1) · Fecal Microbiota Transplantation (1) · Filgrastim (1) · Inotuzumab Ozogamicin (1) · Mycophenolic Acid (1) · O(6)-benzylguanine (1) · Tacrolimus (1) · Temozolomide (1) · Thiotepa (1) · Whole-Body Irradiation (1) · fludarabine (1)
United States (6)
U01CA236215 (1)